Coulter Partners successfully completed a search assignment for Altimmune Inc. (Nasdaq: ALT), and is pleased to announce the placement of biopharmaceutical industry executives Teri Lawver and Jerry Durso to its Board of Directors.Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, MASH and other indications.Commenting on the search work with Coulter Partners, Vipin K. Garg, Ph.D., President and Chief…
Howard Group provides local charity with an affordable and well-equipped
new home
Cambridge, 2nd April 2025: Leading regional property investor and developer Howard Group, is delighted to welcome local charity Papworth Trust - a leading disability charity that supports thousands of people, their families and carers every year - to Unity Campus.
The charity has committed to a five-year lease of 3,990 sq ft of ground floor space in the Iconix 1 building and is an excellent addition to the burgeoning and collaborative community of health and science companies at Unity…
AMSBIO has expanded its biofluid collection and processing capabilities, to now offer an unmatched range of customizable human blood biospecimens from both healthy and disease-state donors to support biomedical research.
Leveraging an extensive network of diverse donors, AMSBIO provides high-quality, ethically sourced samples tailored to specific donor demographics, sample volumes, and processing methods.
Using a fully licensed sample collection and processing facility, AMSBIO can ensure the highest standards of traceability and compliance. The expanded portfolio includes…
Kadans Science Partner (“Kadans”), a leading European investor in the development of ecosystems and real estate with a dedicated focus on knowledge-intensive sectors, has commenced construction on its purpose-built laboratory facility, Versa.
As the second project to be delivered by Kadans within the Tileyard Quarter in King’s Cross, London, this is a significant milestone for both the area and London’s life science sector more generally.
Due to complete in Q2 2026, and located at 4 Brandon Road, Versa will provide 51,500 sq ft of space, designed to accommodate a range of uses from CL2 labs…
Miltenyi Biotec, an innovator of products and services for biomedical research and cell and gene therapies, has announced a strategic partnership with leading developer of life science ecosystems, integrating infrastructure, investment, and venture support, Pioneer Group.
Through this collaboration, Miltenyi Biotec will establish a suite of state-of-the-art instruments at Victoria House, Pioneer’s flagship life sciences centre in London’s Knowledge Quarter. This strategic placement will empower Miltenyi Biotec to accelerate research and development while directly engaging with the site’s…
Read April eNews here 👉 https://shorturl.at/xZ6e9Sponsored by Catalent Pharma Solutions
Featuring:
✅ Reporting on a Month of Support, Celebration and Insights, by Tony Jones, CEO, One Nucleus✅ Logistically Thinking When It Comes To Value Creation with Tushar Madani and Michael O'Kane from CoolReach Healthcare Logistics LTD✅ Global R&D Tax Incentives for SMEs: A Cross-country Comparison by RSM✅ Life Science Financing Summary - Review of February 2025 Data from Venture Valuation AG✅ Why You Should Use a Travel Management Company for Your Next Trip by Romy Frow, Travel Counsellors✅ How…
London, April 1, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, is delighted to announce the strengthening of its management team with the promotion of Penny Sadler as Managing Partner.Penny Sadler brings 30 years of global search experience to her new role, with a specialization in medtech, diagnostics, and life sciences tools. She also possesses deep expertise in Benelux pharmaceuticals, as well as biotech startups and scaleups. As head of Coulter Partners’ Belgium office, she has demonstrated exceptional…
Are you a pre-clinical therapeutics start-up?
Stevenage Bioscience Catalyst’s Catalyser is an accelerator designed to help businesses attract investors and partners, and maximise overall chances of commercial success.
The Triple Chasm framework is used to structure the programme via six interactive sessions on the below topics:
• Market Space Definition
• Proposition Framing
• Customer Definition
• Contingent Technology Management
• IP Management
• Product Synthesis
• Human Capital
• Funding Strategy
• Strategic Positioning
Complimentary CRO services package:
Businesses that take part will…
Read the March edition of our People Pathways newsletter here.
Featuring:
✅One Nucleus upcoming courses✅South Carolina visit✅Apprentice opportunity from Domainex✅Industry news and more...
Oh what a night!
A fantastic array of life science innovators met up at the One Nucleus Annual Awards Dinner in London last night to celebrate their incredible achievements.
Many congratulations to the winners and finalists:
Best Performing Therapeutic Discovery Company of the YearWinner: AviadoBioFinalists: Healx, Resolution Therapeutics
Best Performing R&D Platform Development Company of the YearWinner: Constructive BioFinalists: Nuclera, OutSee
Best Performing New Company Creator of the YearWinner: UCL Business LtdFinalists: Deep Science Ventures, Babraham Research Campus
Best…